Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Merck & Co. Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Common-Size Income Statement
- Analysis of Profitability Ratios
- Analysis of Geographic Areas
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Merck & Co. Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The liquidity position, as indicated by the current, quick, and cash ratios, exhibits fluctuations over the observed period. Generally, the ratios demonstrate a degree of cyclicality, with periods of improvement followed by periods of decline. A notable upward trend is observed in the latter part of the period, particularly in the most recent quarters.
- Current Ratio
- The current ratio remained relatively stable between 1.39 and 1.47 from March 2022 through December 2022. A decline was then observed through December 2023, reaching a low of 1.25. However, the ratio rebounded in the first half of 2024, peaking at 1.47 in March, before stabilizing around 1.36-1.41. Further improvement is evident in the latter quarters of the period, reaching 1.66 in September 2025 and 1.54 in December 2025.
- Quick Ratio
- The quick ratio mirrored the trend of the current ratio to some extent, though with more pronounced declines. It decreased from 0.93 in December 2022 to a low of 0.68 in December 2023. A recovery began in 2024, with the ratio reaching 0.88 in June 2024. A significant increase is then observed, culminating in a ratio of 1.06 in September 2025 and 0.93 in December 2025. This suggests an improving ability to meet short-term obligations with highly liquid assets.
- Cash Ratio
- The cash ratio demonstrated a consistent upward trend from 0.40 in March 2022 to 0.54 in December 2022. A subsequent decline occurred, reaching a low of 0.27 in June 2023. The ratio remained subdued through the first half of 2024, but experienced a substantial increase in the latter half of 2025, reaching 0.64 in September and 0.51 in December. This indicates a strengthening capacity to cover immediate liabilities with cash and cash equivalents.
Overall, the observed trends suggest a period of liquidity challenges in 2023, followed by a strengthening liquidity position in 2024 and 2025. The increases in all three ratios during the latter part of the period indicate improved short-term financial health and a greater ability to meet obligations as they come due.
Current Ratio
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Current assets | |||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||
| Current ratio1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Current Ratio, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The current ratio exhibited fluctuations over the observed period, generally remaining above 1.0, indicating a consistent ability to cover short-term liabilities with short-term assets. However, notable shifts in this ratio are present.
- Overall Trend
- From March 31, 2022, through December 31, 2022, the current ratio demonstrated a slight increasing trend, moving from 1.40 to 1.47. A subsequent decline was observed in the first half of 2023, reaching a low of 1.28 by June 30, 2023. The ratio experienced a partial recovery in the latter half of 2023 and the first half of 2024, peaking at 1.47 by March 31, 2024, before stabilizing around 1.36-1.54 through December 31, 2025.
- Short-Term Decline (2023)
- The decrease in the current ratio during the first half of 2023 warrants attention. This decline coincided with a reduction in current assets from US$35,722 million to US$29,977 million, while current liabilities remained relatively stable. This suggests a potential shift in the composition of short-term assets or an increased reliance on short-term financing during this period.
- Recent Improvement (2024-2025)
- The current ratio showed improvement in the latter part of the analyzed timeframe. This was driven by a significant increase in current assets, particularly noticeable between March 31, 2024, and September 30, 2025, reaching US$47,557 million. While current liabilities also increased, the growth in current assets outpaced that of current liabilities, resulting in a higher current ratio. The ratio peaked at 1.66 on September 30, 2025, before slightly decreasing to 1.54 by December 31, 2025.
- Quarterly Volatility
- The current ratio demonstrated some degree of quarterly volatility throughout the period. For example, a decrease from 1.38 in September 2023 to 1.25 in December 2023, followed by a rebound to 1.47 in March 2024. These fluctuations suggest potential seasonal or cyclical factors influencing the company’s short-term asset and liability management.
In conclusion, the current ratio indicates a generally healthy short-term liquidity position, although fluctuations exist. The observed decline in the first half of 2023 and subsequent recovery require further investigation to understand the underlying drivers and potential implications for the company’s financial health.
Quick Ratio
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||
| Short-term investments | |||||||||||||||||||||
| Accounts receivable, net of allowance for doubtful accounts | |||||||||||||||||||||
| Total quick assets | |||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||
| Quick ratio1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Quick Ratio, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The quick ratio exhibited fluctuations over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrated an increasing trend, peaking in the fourth quarter of 2022, before experiencing periods of decline and subsequent recovery.
- Initial Trend (Q1 2022 - Q4 2022)
- The quick ratio began at 0.84 in the first quarter of 2022 and gradually increased to 0.93 by the end of the year. This suggests an improving ability to meet short-term obligations with the most liquid assets during this timeframe. Total quick assets increased from US$18,756 million to US$22,642 million, while current liabilities also rose, but at a slower pace.
- Decline and Stabilization (Q1 2023 - Q3 2023)
- The first three quarters of 2023 saw a decline in the quick ratio, falling to a low of 0.68 in the third quarter. This coincided with a decrease in total quick assets, from US$20,802 million to US$19,167 million, and a rise in current liabilities to US$25,694 million. The ratio then stabilized in the fourth quarter of 2023, remaining at 0.68.
- Recovery and Peak (Q1 2024 - Q3 2025)
- From the beginning of 2024, the quick ratio began to recover, reaching 0.88 in the second quarter of 2024. It fluctuated between 0.84 and 0.88 through the end of 2024. A significant increase was observed in the third quarter of 2025, with the ratio reaching a peak of 1.06. This improvement was driven by a substantial increase in total quick assets to US$30,334 million, while current liabilities remained relatively stable.
- Final Period (Q4 2025)
- The quick ratio experienced a slight decrease in the final quarter of 2025, settling at 0.93. This suggests a minor reduction in the company’s ability to cover its immediate liabilities with highly liquid assets, although it remained at a relatively healthy level.
Overall, the quick ratio demonstrates a cyclical pattern with periods of improvement, decline, and recovery. The most notable change is the significant increase in the ratio during the third quarter of 2025, indicating a strengthened short-term liquidity position.
Cash Ratio
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||
| Short-term investments | |||||||||||||||||||||
| Total cash assets | |||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||
| Cash ratio1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Cash Ratio, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The cash ratio exhibited fluctuations over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrated an increasing trend, followed by periods of decline and subsequent recovery. A notable surge is observed in the later part of the period.
- Initial Trend (Mar 31, 2022 – Dec 31, 2022)
- The cash ratio increased consistently from 0.40 in March 2022 to 0.54 in December 2022. This indicates a strengthening ability to cover current liabilities with immediately available cash during this timeframe. The increase suggests improved short-term liquidity or a strategic build-up of cash reserves.
- Decline and Stabilization (Mar 31, 2023 – Sep 30, 2023)
- Following the peak in December 2022, the cash ratio experienced a decline, reaching a low of 0.27 in June 2023. It partially recovered to 0.38 by September 2023, but remained below the levels observed in 2022. This period suggests a potential utilization of cash reserves or an increase in current liabilities that outpaced cash holdings.
- Further Decline and Recovery (Dec 31, 2023 – Jun 30, 2024)
- The ratio continued to decline to 0.22 in December 2023, before rebounding to 0.44 in March 2024 and further increasing to 0.49 in June 2024. This recovery suggests a renewed focus on strengthening the short-term liquidity position.
- Recent Performance (Sep 30, 2024 – Dec 31, 2025)
- The cash ratio remained relatively stable between 0.48 and 0.49 through September 2024, then increased significantly to 0.64 in September 2025. It slightly decreased to 0.51 by December 2025. This recent increase indicates a substantial improvement in the company’s ability to meet its short-term obligations with cash, potentially due to increased cash inflows or a reduction in current liabilities.
Overall, the cash ratio demonstrates a cyclical pattern. While periods of decline were observed, the ratio generally trended upwards over the entire period, culminating in a strong position by the end of 2025. The fluctuations suggest active management of cash and liabilities, responding to changing business conditions.